Pfizer Inc.
BTLA fusion protein agonists and uses thereof

Last updated:

Abstract:

The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.

Status:
Grant
Type:

Utility

Filling date:

29 Jun 2016

Issue date:

30 Mar 2021